Key result
Recent advances in next-generation sequencing, stem cell-derived cardiomyocytes, and novel targeted therapies are opening new avenues for precision medicine in the management of cardiomyopathy.
Recent advances in genetics and stem cell modeling are paving the way for precision medicine and novel targeted therapies in cardiomyopathy.
Should not yet change cardiomyopathy management; leaves open clinical translation of precision approaches.
Cardiomyopathy is a disease of the heart muscle leading to abnormal structure or function in the absence of coronary artery disease, hypertension, or valvular or congenital heart disease. Currently, cardiomyopathy is the leading diagnosis of heart transplant patients worldwide. Incorporation of next-generation sequencing strategies will likely revolutionize genetic testing in cardiomyopathy. The use of patient-specific pluripotent stem cell-derived cardiomyocytes for disease modeling and therapeutic testing has opened a new avenue for precision medicine in cardiomyopathy. Stem cell therapy, gene therapy, interfering RNA, and small molecules are actively being evaluated in clinical trials.
No takes yet. Share an insight, caveat, or question.
Álvarez et al. (2017) conducted a review in Cardiomyopathy. Recent advances in next-generation sequencing, stem cell-derived cardiomyocytes, and novel targeted therapies are opening new avenues for precision medicine in the management of cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: